Accretive Health, Inc.; Analysis of Proposed Consent Order To Aid Public Comment, 2175-2177 [2014-00373]
Download as PDF
Federal Register / Vol. 79, No. 8 / Monday, January 13, 2014 / Notices
2175
EARLY TERMINATIONS GRANTED—Continued
DECEMBER 1, 2013 THRU DECEMBER 31, 2013
12/23/2013
20140253 ......
20140303 ......
20140318 ......
G
G
G
Henry Schein, Inc.; HealthPoint Capital Partners II, LP; Henry Schein, Inc.
NCR Corporation; Fandango Holdings Corporation; NCR Corporation.
Post Holdings, Inc.; TA XI L.P.; Post Holdings, Inc.
12/24/2013
20140300
20140310
20140317
20140322
20140324
20140328
......
......
......
......
......
......
G
G
G
G
G
G
LKQ Corporation; Platinum Equity Capital Partners II, L.P.; LKQ Corporation.
Calpine Corporation; Wayzata Opportunities Fund II, L.P.; Calpine Corporation.
Genuine Parts Company; Mickey M. Hamano; Genuine Parts Company.
David D. Smith; Robert C. Russel; David D. Smith.
Steven B. Fader; Robert C. Russel; Steven B. Fader.
Fairfax Financial Holdings Ltd.; EXCO Resources, Inc.; Fairfax Financial Holdings Ltd.
12/26/2013
20140299 ......
G
DXP Enterprises, Inc.; Champlain Capital Partners, L.P.; DXP Enterprises, Inc.
12/31/2013
20140307
20140319
20140329
20140330
20140332
20140333
20140335
20140338
20140339
20140343
20140346
......
......
......
......
......
......
......
......
......
......
......
G
G
G
G
G
G
G
G
G
G
G
20140353 ......
G
JDS Uniphase Corporation; Thoma Bravo Fund X, L.P.; JDS Uniphase Corporation.
Bertram Growth Capital II, L.P.; Maxcess International, LLC; Bertram Growth Capital II, L.P.
Mark Mitchell; Centene Corporation; Mark Mitchell.
Centene Corporation; Mark Mitchell; Centene Corporation.
Blackstone Capital Partners (Caymen) V–NQ L.P.; Todd Batten; Blackstone Capital Partners (Caymen) V–NQ L.P.
E. Merck KG; AZ Electronic Materials S.A.; E. Merck KG.
Clayton, Dubilier & Rice Fund IX, L.P.; PharMEDium Healthcare Corporation; Clayton, Dubilier & Rice Fund IX, L.P.
Macquarie Infrastructure Company LLC; Martin F. Greenberg; Macquarie Infrastructure Company LLC.
Post Holdings, Inc.; Tricor Pacific Capital Partners (Fund IV), LP; Post Holdings, Inc.
Seneca Foods Corporation; All Veg, LLC; Seneca Foods Corporation.
Audax Private Equity Fund IV AIV, L.P.; Evangelos P. Proimos Living Trust UAD 11/19/2003; Audax Private Equity Fund
IV AIV, L.P.
Cummins Inc.; Ben J. Strafuss; Cummins Inc.
FOR FURTHER INFORMATION CONTACT:
Renee Chapman, Contact
Representative; or Theresa Kingsberry,
Legal Assistant, Federal Trade
Commission, Premerger Notification
Office, Bureau of Competition, Room H–
303, Washington, DC 20580, (202) 326–
3100.
By direction of the Commission.
Donald S. Clark,
Secretary.
[FR Doc. 2014–00240 Filed 1–10–14; 8:45 am]
BILLING CODE 6750–01–M
FEDERAL TRADE COMMISSION
[File No. 122 3077]
Accretive Health, Inc.; Analysis of
Proposed Consent Order To Aid Public
Comment
Federal Trade Commission.
Proposed Consent Agreement.
AGENCY:
tkelley on DSK3SPTVN1PROD with NOTICES
ACTION:
The consent agreement in this
matter settles alleged violations of
federal law prohibiting unfair or
deceptive acts or practices or unfair
methods of competition. The attached
Analysis of Proposed Consent Order to
Aid Public Comment describes both the
SUMMARY:
VerDate Mar<15>2010
16:40 Jan 10, 2014
Jkt 232001
allegations in the draft complaint and
the terms of the consent order—
embodied in the consent agreement—
that would settle these allegations.
DATES: Comments must be received on
or before January 30, 2014.
ADDRESSES: Interested parties may file a
comment at https://
ftcpublic.commentworks.com/ftc/
accretiveconsent online or on paper, by
following the instructions in the
Request for Comment part of the
SUPPLEMENTARY INFORMATION section
below. Write ‘‘Accretive Health, Inc.Consent Agreement; File No. 122 3077’’
on your comment and file your
comment online at https://
ftcpublic.commentworks.com/ftc/
accretiveconsenthttps://
ftcpublic.commentworks.com/ftc/
fidelitynationalconsent by following the
instructions on the web-based form. If
you prefer to file your comment on
paper, mail or deliver your comment to
the following address: Federal Trade
Commission, Office of the Secretary,
Room H–113 (Annex D), 600
Pennsylvania Avenue NW., Washington,
DC 20580.
FOR FURTHER INFORMATION CONTACT:
David Lincicum, Bureau of Consumer
Protection, (202–326–2773), 600
PO 00000
Frm 00029
Fmt 4703
Sfmt 4703
Pennsylvania Avenue NW., Washington,
DC 20580.
Pursuant
to Section 6(f) of the Federal Trade
Commission Act, 15 U.S.C. 46(f), and
FTC Rule 2.34, 16 CFR 2.34, notice is
hereby given that the above-captioned
consent agreement containing a consent
order to cease and desist, having been
filed with and accepted, subject to final
approval, by the Commission, has been
placed on the public record for a period
of thirty (30) days. The following
Analysis to Aid Public Comment
describes the terms of the consent
agreement, and the allegations in the
complaint. An electronic copy of the
full text of the consent agreement
package can be obtained from the FTC
Home Page (for December 31, 2013), on
the World Wide Web, at https://
www.ftc.gov/os/actions.shtm. A paper
copy can be obtained from the FTC
Public Reference Room, Room 130–H,
600 Pennsylvania Avenue NW.,
Washington, DC 20580, either in person
or by calling (202) 326–2222.
You can file a comment online or on
paper. For the Commission to consider
your comment, we must receive it on or
before January 30, 2014. Write
‘‘Accretive Health, Inc.- Consent
SUPPLEMENTARY INFORMATION:
E:\FR\FM\13JAN1.SGM
13JAN1
tkelley on DSK3SPTVN1PROD with NOTICES
2176
Federal Register / Vol. 79, No. 8 / Monday, January 13, 2014 / Notices
Agreement; File No. 122 3077’’ on your
comment. Your comment—including
your name and your state—will be
placed on the public record of this
proceeding, including, to the extent
practicable, on the public Commission
Web site, at https://www.ftc.gov/os/
publiccomments.shtm. As a matter of
discretion, the Commission tries to
remove individuals’ home contact
information from comments before
placing them on the Commission Web
site.
Because your comment will be made
public, you are solely responsible for
making sure that your comment does
not include any sensitive personal
information, like anyone’s Social
Security number, date of birth, driver’s
license number or other state
identification number or foreign country
equivalent, passport number, financial
account number, or credit or debit card
number. You are also solely responsible
for making sure that your comment does
not include any sensitive health
information, like medical records or
other individually identifiable health
information. In addition, do not include
any ‘‘[t]rade secret or any commercial or
financial information which . . . is
privileged or confidential,’’ as discussed
in Section 6(f) of the FTC Act, 15 U.S.C.
46(f), and FTC Rule 4.10(a)(2), 16 CFR
4.10(a)(2). In particular, do not include
competitively sensitive information
such as costs, sales statistics,
inventories, formulas, patterns, devices,
manufacturing processes, or customer
names.
If you want the Commission to give
your comment confidential treatment,
you must file it in paper form, with a
request for confidential treatment, and
you have to follow the procedure
explained in FTC Rule 4.9(c), 16 CFR
4.9(c).1 Your comment will be kept
confidential only if the FTC General
Counsel, in his or her sole discretion,
grants your request in accordance with
the law and the public interest.
Postal mail addressed to the
Commission is subject to delay due to
heightened security screening. As a
result, we encourage you to submit your
comments online. To make sure that the
Commission considers your online
comment, you must file it at https://
ftcpublic.commentworks.com/ftc/
accretiveconsent by following the
instructions on the web-based form. If
this Notice appears at https://
www.regulations.gov/#!home, you also
1 In particular, the written request for confidential
treatment that accompanies the comment must
include the factual and legal basis for the request,
and must identify the specific portions of the
comment to be withheld from the public record. See
FTC Rule 4.9(c), 16 CFR 4.9(c).
VerDate Mar<15>2010
16:40 Jan 10, 2014
Jkt 232001
may file a comment through that Web
site.
If you file your comment on paper,
write ‘‘Accretive Health, Inc.- Consent
Agreement; File No. 122 3077’’ on your
comment and on the envelope, and mail
or deliver it to the following address:
Federal Trade Commission, Office of the
Secretary, Room H–113 (Annex D), 600
Pennsylvania Avenue NW., Washington,
DC 20580. If possible, submit your
paper comment to the Commission by
courier or overnight service.
Visit the Commission Web site at
https://www.ftc.gov to read this Notice
and the news release describing it. The
FTC Act and other laws that the
Commission administers permit the
collection of public comments to
consider and use in this proceeding as
appropriate. The Commission will
consider all timely and responsive
public comments that it receives on or
before January 30, 2014. You can find
more information, including routine
uses permitted by the Privacy Act, in
the Commission’s privacy policy, at
https://www.ftc.gov/ftc/privacy.htm.
Analysis of Proposed Consent Order To
Aid Public Comment
The Federal Trade Commission has
accepted, subject to final approval, a
consent order applicable to Accretive
Health Systems, Inc.
The proposed consent order has been
placed on the public record for thirty
(30) days for receipt of comments by
interested persons. Comments received
during this period will become part of
the public record. After thirty (30) days,
the Commission will again review the
agreement and the comments received,
and will decide whether it should
withdraw from the agreement and take
appropriate action or make final the
agreement’s proposed order.
Accretive Health enters into service
agreements with hospital systems
around the country to provide services
related to the hospital systems’
‘‘revenue cycle’’ operations. Revenue
cycle operations include registration,
transcription, coding and medical
documentation, billing, pricing, and
collection of past due accounts. In
exchange for these services, hospital
systems pay Accretive Health both fixed
fees and incentive payments based on a
percentage of the monetary benefit from
increased revenues. Accretive Health
employees work at hospital facilities to
assist with these services. As part of its
service to client hospitals, Accretive
Health collects, maintains, and has
access to information about hospitals’
patients, including sensitive health and
personal information. This information
may include patient names, dates of
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
birth, billing information, diagnostic
information, and Social Security
numbers.
The Commission’s complaint alleges
that Accretive Health unfairly failed to
provide reasonable and appropriate
security for consumers’ personal
information it collected and maintained
by engaging in a number of practices
that, taken together, unreasonably and
unnecessarily exposed consumers’
personal data to unauthorized access.
Among other things, Accretive Health
created unnecessary risks of
unauthorized access or theft of personal
information by:
a. Transporting laptops containing
personal information in a manner that
made them vulnerable to theft or other
misappropriation;
b. Failing to adequately restrict access
to, or copying of, personal information
based on an employee’s need for
information;
c. Failing to ensure that employees
removed information from their
computers for which they no longer had
a business need; and
d. Using consumers’ personal
information in training sessions with
employees and failing to ensure that the
information was removed from
employees’ computers following the
training.
The complaint further alleges that
these failures contributed to a July 2011
incident in Minneapolis, Minnesota in
which an Accretive Health laptop
containing over 600 files with over 20
million pieces of information related to
23,000 patients was left in the locked
passenger compartment of the
employee’s car and stolen. The laptop
included sensitive health and personal
information, including patient names,
dates of birth, billing information,
diagnostic information, and Social
Security numbers. The user of this
laptop had data that was not necessary
to perform his job.
The proposed order contains
provisions designed to prevent
Accretive Health from engaging in the
future in practices similar to those
alleged in the complaint.
Part II of the proposed order requires
Accretive Health to establish and
maintain, or continue to maintain, a
comprehensive information security
program that is reasonably designed to
protect the security, confidentiality, and
integrity of personal information
collected from or about consumers. The
security program must contain
administrative, technical, and physical
safeguards appropriate to Accretive
Health’s size and complexity, nature
and scope of its activities, and the
sensitivity of the information collected
E:\FR\FM\13JAN1.SGM
13JAN1
tkelley on DSK3SPTVN1PROD with NOTICES
Federal Register / Vol. 79, No. 8 / Monday, January 13, 2014 / Notices
from or about consumers. Specifically,
the proposed order requires Accretive
Health to:
• Designate an employee or
employees to coordinate and be
accountable for the information security
program;
• identify material internal and
external risks to the security,
confidentiality, and integrity of personal
information that could result in the
unauthorized disclosure, misuse, loss,
alteration, destruction, or other
compromise of such information, and
assess the sufficiency of any safeguards
in place to control these risks;
• design and implement reasonable
safeguards to control the risks identified
through risk assessment, and regularly
test or monitor the effectiveness of the
safeguards’ key controls, systems, and
procedures;
• develop and use reasonable steps to
select and retain service providers
capable of appropriately safeguarding
personal information they receive from
Accretive Health, and require service
providers by contract to implement and
maintain appropriate safeguards; and
• evaluate and adjust its information
security program in light of the results
of testing and monitoring, any material
changes to operations or business
arrangement, or any other circumstances
that it knows or has reason to know may
have a material impact on its
information security program.
Part III of the proposed order requires
Accretive Health to obtain within the
first one hundred eighty (180) days after
service of the order, and on a biennial
basis thereafter for a period of twenty
(20) years, an assessment and report
from a qualified, objective, independent
third-party professional, certifying,
among other things, that: (1) It has in
place a security program that provides
protections that meet or exceed the
protections required by Part II of the
proposed order; and (2) its security
program is operating with sufficient
effectiveness to provide reasonable
assurance that the security,
confidentiality, and integrity of
sensitive consumer, information has
been protected.
Parts IV through VIII of the proposed
order are reporting and compliance
provisions. Part IV requires Accretive
Health to retain documents relating to
its compliance with the order. For most
records, the order requires that the
documents be retained for a five-year
period. For the third-party assessments
and supporting documents, Accretive
Health must retain the documents for a
period of three years after the date that
each assessment is prepared. Part V
requires dissemination of the order now
VerDate Mar<15>2010
16:40 Jan 10, 2014
Jkt 232001
and in the future to all current and
future principals, officers, directors, and
managers, and to persons with
responsibilities relating to the subject
matter of the order. Part VI ensures
notification to the FTC of changes in
corporate status. Part VII mandates that
Accretive Health submit a compliance
report to the FTC within 60 days, and
periodically thereafter as requested. Part
VIII is a provision ‘‘sunsetting’’ the
order after twenty (20) years, with
certain exceptions.
The purpose of this analysis is to
facilitate public comment on the
proposed order. It is not intended to
constitute an official interpretation of
the proposed complaint or order or to
modify the order’s terms in any way.
By direction of the Commission.
Janice Podoll Frankle,
Acting Secretary.
[FR Doc. 2014–00373 Filed 1–10–14; 8:45 am]
BILLING CODE 6750–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0001]
Request for Notification From Industry
Organizations Interested in
Participating in the Selection Process
for Nonvoting Industry
Representatives and Request for
Nominations for Nonvoting Industry
Representatives on the Pharmacy
Compounding Advisory Committee
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is requesting that
industry organizations interested in
participating in the selection of
nonvoting industry representatives to
represent the interests of the pharmacy
compounding industry and the
pharmaceutical manufacturing industry
on the Pharmacy Compounding
Advisory Committee for the Center for
Drug Evaluation and Research notify
FDA in writing. A nominee may either
be self-nominated or nominated by an
organization to serve as a nonvoting
industry representative. Nominations
will be accepted for two vacancies
effective with this notice.
FDA seeks to include the views of
women and men, members of all racial
and ethnic groups, and individuals with
and without disabilities on its advisory
committees, and therefore, encourages
nominations of appropriately qualified
SUMMARY:
PO 00000
Frm 00031
Fmt 4703
Sfmt 4703
2177
candidates from these groups.
Specifically, in this document,
nominations for nonvoting
representatives of industry interests are
encouraged from the pharmacy
compounding industry and the
pharmaceutical manufacturing industry.
DATES: Any industry organization
interested in participating in the
selection of appropriate nonvoting
members to represent the interests of the
pharmacy compounding industry and
the pharmaceutical manufacturing
industry should send a letter stating the
interest to FDA by February 12, 2014,
for the vacancies listed in this notice.
Concurrently, nomination materials for
prospective candidates should be sent to
FDA by February 12, 2014.
ADDRESSES: All letters of interest and
nominations should be submitted
electronically to PCAC@fda.hhs.gov, or
in writing by mail to Jayne E. Peterson,
Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993.
FOR FURTHER INFORMATION CONTACT:
Jayne E. Peterson, Center for Drug
Evaluation and Research, Food and
Drug Administration, 10903 New
Hampshire Ave., Bldg. 31, Rm. 2417,
Silver Spring, MD 20993, 301–796–
9001, FAX: 301–847–8533, email:
PCAC@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: The
Agency requests nominations for
nonvoting industry representatives on
the Pharmacy Compounding Advisory
Committee (the Committee) to represent
the interests of the pharmacy
compounding industry and the
pharmaceutical manufacturing industry.
I. Pharmacy Compounding Advisory
Committee
The Committee advises the
Commissioner of Food and Drugs (the
Commissioner) or designee in
discharging responsibilities as they
relate to the regulation of compounded
drug products. The Committee provides
advice on scientific, technical, and
medical issues concerning drug
compounding under sections 503A and
503B of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 353a and 353b),
and as required, any other product for
which FDA has regulatory
responsibility. The Committee also
makes appropriate recommendations to
the Commissioner.
The Committee will include one or
more nonvoting members who represent
industry interests. These members will
include one representative of the
pharmacy compounding industry and
E:\FR\FM\13JAN1.SGM
13JAN1
Agencies
[Federal Register Volume 79, Number 8 (Monday, January 13, 2014)]
[Notices]
[Pages 2175-2177]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-00373]
-----------------------------------------------------------------------
FEDERAL TRADE COMMISSION
[File No. 122 3077]
Accretive Health, Inc.; Analysis of Proposed Consent Order To Aid
Public Comment
AGENCY: Federal Trade Commission.
ACTION: Proposed Consent Agreement.
-----------------------------------------------------------------------
SUMMARY: The consent agreement in this matter settles alleged
violations of federal law prohibiting unfair or deceptive acts or
practices or unfair methods of competition. The attached Analysis of
Proposed Consent Order to Aid Public Comment describes both the
allegations in the draft complaint and the terms of the consent order--
embodied in the consent agreement--that would settle these allegations.
DATES: Comments must be received on or before January 30, 2014.
ADDRESSES: Interested parties may file a comment at https://ftcpublic.commentworks.com/ftc/accretiveconsent online or on paper, by
following the instructions in the Request for Comment part of the
SUPPLEMENTARY INFORMATION section below. Write ``Accretive Health,
Inc.-Consent Agreement; File No. 122 3077'' on your comment and file
your comment online at https://ftcpublic.commentworks.com/ftc/accretiveconsenthttps://ftcpublic.commentworks.com/ftc/fidelitynationalconsent by following the instructions on the web-based
form. If you prefer to file your comment on paper, mail or deliver your
comment to the following address: Federal Trade Commission, Office of
the Secretary, Room H-113 (Annex D), 600 Pennsylvania Avenue NW.,
Washington, DC 20580.
FOR FURTHER INFORMATION CONTACT: David Lincicum, Bureau of Consumer
Protection, (202-326-2773), 600 Pennsylvania Avenue NW., Washington, DC
20580.
SUPPLEMENTARY INFORMATION: Pursuant to Section 6(f) of the Federal
Trade Commission Act, 15 U.S.C. 46(f), and FTC Rule 2.34, 16 CFR 2.34,
notice is hereby given that the above-captioned consent agreement
containing a consent order to cease and desist, having been filed with
and accepted, subject to final approval, by the Commission, has been
placed on the public record for a period of thirty (30) days. The
following Analysis to Aid Public Comment describes the terms of the
consent agreement, and the allegations in the complaint. An electronic
copy of the full text of the consent agreement package can be obtained
from the FTC Home Page (for December 31, 2013), on the World Wide Web,
at https://www.ftc.gov/os/actions.shtm. A paper copy can be obtained
from the FTC Public Reference Room, Room 130-H, 600 Pennsylvania Avenue
NW., Washington, DC 20580, either in person or by calling (202) 326-
2222.
You can file a comment online or on paper. For the Commission to
consider your comment, we must receive it on or before January 30,
2014. Write ``Accretive Health, Inc.- Consent
[[Page 2176]]
Agreement; File No. 122 3077'' on your comment. Your comment--including
your name and your state--will be placed on the public record of this
proceeding, including, to the extent practicable, on the public
Commission Web site, at https://www.ftc.gov/os/publiccomments.shtm. As a
matter of discretion, the Commission tries to remove individuals' home
contact information from comments before placing them on the Commission
Web site.
Because your comment will be made public, you are solely
responsible for making sure that your comment does not include any
sensitive personal information, like anyone's Social Security number,
date of birth, driver's license number or other state identification
number or foreign country equivalent, passport number, financial
account number, or credit or debit card number. You are also solely
responsible for making sure that your comment does not include any
sensitive health information, like medical records or other
individually identifiable health information. In addition, do not
include any ``[t]rade secret or any commercial or financial information
which . . . is privileged or confidential,'' as discussed in Section
6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR
4.10(a)(2). In particular, do not include competitively sensitive
information such as costs, sales statistics, inventories, formulas,
patterns, devices, manufacturing processes, or customer names.
If you want the Commission to give your comment confidential
treatment, you must file it in paper form, with a request for
confidential treatment, and you have to follow the procedure explained
in FTC Rule 4.9(c), 16 CFR 4.9(c).\1\ Your comment will be kept
confidential only if the FTC General Counsel, in his or her sole
discretion, grants your request in accordance with the law and the
public interest.
---------------------------------------------------------------------------
\1\ In particular, the written request for confidential
treatment that accompanies the comment must include the factual and
legal basis for the request, and must identify the specific portions
of the comment to be withheld from the public record. See FTC Rule
4.9(c), 16 CFR 4.9(c).
---------------------------------------------------------------------------
Postal mail addressed to the Commission is subject to delay due to
heightened security screening. As a result, we encourage you to submit
your comments online. To make sure that the Commission considers your
online comment, you must file it at https://ftcpublic.commentworks.com/ftc/accretiveconsent by following the instructions on the web-based
form. If this Notice appears at https://www.regulations.gov/#!home, you
also may file a comment through that Web site.
If you file your comment on paper, write ``Accretive Health, Inc.-
Consent Agreement; File No. 122 3077'' on your comment and on the
envelope, and mail or deliver it to the following address: Federal
Trade Commission, Office of the Secretary, Room H-113 (Annex D), 600
Pennsylvania Avenue NW., Washington, DC 20580. If possible, submit your
paper comment to the Commission by courier or overnight service.
Visit the Commission Web site at https://www.ftc.gov to read this
Notice and the news release describing it. The FTC Act and other laws
that the Commission administers permit the collection of public
comments to consider and use in this proceeding as appropriate. The
Commission will consider all timely and responsive public comments that
it receives on or before January 30, 2014. You can find more
information, including routine uses permitted by the Privacy Act, in
the Commission's privacy policy, at https://www.ftc.gov/ftc/privacy.htm.
Analysis of Proposed Consent Order To Aid Public Comment
The Federal Trade Commission has accepted, subject to final
approval, a consent order applicable to Accretive Health Systems, Inc.
The proposed consent order has been placed on the public record for
thirty (30) days for receipt of comments by interested persons.
Comments received during this period will become part of the public
record. After thirty (30) days, the Commission will again review the
agreement and the comments received, and will decide whether it should
withdraw from the agreement and take appropriate action or make final
the agreement's proposed order.
Accretive Health enters into service agreements with hospital
systems around the country to provide services related to the hospital
systems' ``revenue cycle'' operations. Revenue cycle operations include
registration, transcription, coding and medical documentation, billing,
pricing, and collection of past due accounts. In exchange for these
services, hospital systems pay Accretive Health both fixed fees and
incentive payments based on a percentage of the monetary benefit from
increased revenues. Accretive Health employees work at hospital
facilities to assist with these services. As part of its service to
client hospitals, Accretive Health collects, maintains, and has access
to information about hospitals' patients, including sensitive health
and personal information. This information may include patient names,
dates of birth, billing information, diagnostic information, and Social
Security numbers.
The Commission's complaint alleges that Accretive Health unfairly
failed to provide reasonable and appropriate security for consumers'
personal information it collected and maintained by engaging in a
number of practices that, taken together, unreasonably and
unnecessarily exposed consumers' personal data to unauthorized access.
Among other things, Accretive Health created unnecessary risks of
unauthorized access or theft of personal information by:
a. Transporting laptops containing personal information in a manner
that made them vulnerable to theft or other misappropriation;
b. Failing to adequately restrict access to, or copying of,
personal information based on an employee's need for information;
c. Failing to ensure that employees removed information from their
computers for which they no longer had a business need; and
d. Using consumers' personal information in training sessions with
employees and failing to ensure that the information was removed from
employees' computers following the training.
The complaint further alleges that these failures contributed to a
July 2011 incident in Minneapolis, Minnesota in which an Accretive
Health laptop containing over 600 files with over 20 million pieces of
information related to 23,000 patients was left in the locked passenger
compartment of the employee's car and stolen. The laptop included
sensitive health and personal information, including patient names,
dates of birth, billing information, diagnostic information, and Social
Security numbers. The user of this laptop had data that was not
necessary to perform his job.
The proposed order contains provisions designed to prevent
Accretive Health from engaging in the future in practices similar to
those alleged in the complaint.
Part II of the proposed order requires Accretive Health to
establish and maintain, or continue to maintain, a comprehensive
information security program that is reasonably designed to protect the
security, confidentiality, and integrity of personal information
collected from or about consumers. The security program must contain
administrative, technical, and physical safeguards appropriate to
Accretive Health's size and complexity, nature and scope of its
activities, and the sensitivity of the information collected
[[Page 2177]]
from or about consumers. Specifically, the proposed order requires
Accretive Health to:
Designate an employee or employees to coordinate and be
accountable for the information security program;
identify material internal and external risks to the
security, confidentiality, and integrity of personal information that
could result in the unauthorized disclosure, misuse, loss, alteration,
destruction, or other compromise of such information, and assess the
sufficiency of any safeguards in place to control these risks;
design and implement reasonable safeguards to control the
risks identified through risk assessment, and regularly test or monitor
the effectiveness of the safeguards' key controls, systems, and
procedures;
develop and use reasonable steps to select and retain
service providers capable of appropriately safeguarding personal
information they receive from Accretive Health, and require service
providers by contract to implement and maintain appropriate safeguards;
and
evaluate and adjust its information security program in
light of the results of testing and monitoring, any material changes to
operations or business arrangement, or any other circumstances that it
knows or has reason to know may have a material impact on its
information security program.
Part III of the proposed order requires Accretive Health to obtain
within the first one hundred eighty (180) days after service of the
order, and on a biennial basis thereafter for a period of twenty (20)
years, an assessment and report from a qualified, objective,
independent third-party professional, certifying, among other things,
that: (1) It has in place a security program that provides protections
that meet or exceed the protections required by Part II of the proposed
order; and (2) its security program is operating with sufficient
effectiveness to provide reasonable assurance that the security,
confidentiality, and integrity of sensitive consumer, information has
been protected.
Parts IV through VIII of the proposed order are reporting and
compliance provisions. Part IV requires Accretive Health to retain
documents relating to its compliance with the order. For most records,
the order requires that the documents be retained for a five-year
period. For the third-party assessments and supporting documents,
Accretive Health must retain the documents for a period of three years
after the date that each assessment is prepared. Part V requires
dissemination of the order now and in the future to all current and
future principals, officers, directors, and managers, and to persons
with responsibilities relating to the subject matter of the order. Part
VI ensures notification to the FTC of changes in corporate status. Part
VII mandates that Accretive Health submit a compliance report to the
FTC within 60 days, and periodically thereafter as requested. Part VIII
is a provision ``sunsetting'' the order after twenty (20) years, with
certain exceptions.
The purpose of this analysis is to facilitate public comment on the
proposed order. It is not intended to constitute an official
interpretation of the proposed complaint or order or to modify the
order's terms in any way.
By direction of the Commission.
Janice Podoll Frankle,
Acting Secretary.
[FR Doc. 2014-00373 Filed 1-10-14; 8:45 am]
BILLING CODE 6750-01-P